{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:55:09Z","timestamp":1790700909248,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.lpm.2017.01.001","type":"journal-article","created":{"date-parts":[[2017,2,9]],"date-time":"2017-02-09T03:17:21Z","timestamp":1486610241000},"page":"175-181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":157,"special_numbering":"P1","title":["Epidemiology, environmental risk factors and genetics of Parkinson's disease"],"prefix":"10.1016","volume":"46","author":[{"given":"Anna","family":"Delamarre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wassilios G.","family":"Meissner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.lpm.2017.01.001_bib0290","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/mds.25945","article-title":"The prevalence of Parkinson's disease: a systematic review and meta-analysis","volume":"29","author":"Pringsheim","year":"2014","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.lpm.2017.01.001_bib0295","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1159\/000445751","article-title":"The incidence of Parkinson's disease: a systematic review and meta-analysis","volume":"46","author":"Hirsch","year":"2016","journal-title":"Neuroepidemiology"},{"issue":"7","key":"10.1016\/j.lpm.2017.01.001_bib0300","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1001\/archneur.64.7.990","article-title":"Pooled analysis of tobacco use and risk of Parkinson disease","volume":"64","author":"Ritz","year":"2007","journal-title":"Arch Neurol"},{"issue":"4","key":"10.1016\/j.lpm.2017.01.001_bib0305","doi-asserted-by":"crossref","first-page":"e0151841","DOI":"10.1371\/journal.pone.0151841","article-title":"Association between Parkinson's disease and cigarette smoking, rural living, well-water consumption, farming and pesticide use: systematic review and meta-analysis","volume":"11","author":"Breckenridge","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.lpm.2017.01.001_bib0310","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/ana.24385","article-title":"Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder: a multicenter study","volume":"77","author":"Postuma","year":"2015","journal-title":"Ann Neurol"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.lpm.2017.01.001_bib0315","doi-asserted-by":"crossref","first-page":"S221","DOI":"10.3233\/JAD-2010-091525","article-title":"Caffeine exposure and the risk of Parkinson's disease: a systematic review and meta-analysis of observational studies","volume":"20","author":"Costa","year":"2010","journal-title":"J Alzheimers Dis"},{"issue":"10","key":"10.1016\/j.lpm.2017.01.001_bib0320","doi-asserted-by":"crossref","first-page":"RC143","DOI":"10.1523\/JNEUROSCI.21-10-j0001.2001","article-title":"Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease","volume":"21","author":"Chen","year":"2001","journal-title":"J Neurosci"},{"issue":"5","key":"10.1016\/j.lpm.2017.01.001_bib0325","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/aje\/kwm338","article-title":"Differential effects of black versus green tea on risk of Parkinson's disease in the Singapore Chinese Health Study","volume":"167","author":"Tan","year":"2008","journal-title":"Am J Epidemiol"},{"issue":"4","key":"10.1016\/j.lpm.2017.01.001_bib0330","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/ana.21717","article-title":"Professional exposure to pesticides and Parkinson disease","volume":"66","author":"Elbaz","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.lpm.2017.01.001_bib0335","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.envint.2012.05.004","article-title":"Occupational exposure to pesticides and Parkinson's disease: a systematic review and meta-analysis of cohort studies","volume":"46","author":"Van Maele-Fabry","year":"2012","journal-title":"Environ Int"},{"issue":"6","key":"10.1016\/j.lpm.2017.01.001_bib0340","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/archneurol.2010.101","article-title":"Interaction between ABCB1 and professional exposure to organochlorine insecticides in Parkinson disease","volume":"67","author":"Dutheil","year":"2010","journal-title":"Arch Neurol"},{"issue":"12","key":"10.1016\/j.lpm.2017.01.001_bib0345","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.2337\/dc11-1584","article-title":"Diabetes and risk of Parkinson's disease: a systematic review and meta-analysis","volume":"34","author":"Cereda","year":"2011","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.lpm.2017.01.001_bib0350","doi-asserted-by":"crossref","first-page":"e85781","DOI":"10.1371\/journal.pone.0085781","article-title":"Diabetes and risk of Parkinson's disease: an updated meta-analysis of case-control studies","volume":"9","author":"Lu","year":"2014","journal-title":"PLoS One"},{"issue":"18","key":"10.1016\/j.lpm.2017.01.001_bib0355","doi-asserted-by":"crossref","first-page":"e3549","DOI":"10.1097\/MD.0000000000003549","article-title":"Risk of Parkinson disease in diabetes mellitus: an updated meta-analysis of population-based cohort studies","volume":"95","author":"Yue","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"7","key":"10.1016\/j.lpm.2017.01.001_bib0360","doi-asserted-by":"crossref","first-page":"e1001854","DOI":"10.1371\/journal.pmed.1001854","article-title":"Glitazone treatment and incidence of parkinson's Disease among people with diabetes: a retrospective cohort study","volume":"12","author":"Brauer","year":"2015","journal-title":"PLoS Med"},{"issue":"9","key":"10.1016\/j.lpm.2017.01.001_bib0365","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1002\/mds.26734","article-title":"Reduced incidence of Parkinson's disease after dipeptidyl peptidase-4 inhibitors\u00a0\u2013\u00a0A nationwide case-control study","volume":"31","author":"Svenningsson","year":"2016","journal-title":"Mov Disord"},{"issue":"8","key":"10.1016\/j.lpm.2017.01.001_bib0370","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1474-4422(15)00144-1","article-title":"Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial","volume":"14","author":"NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators","year":"2015","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.lpm.2017.01.001_bib0375","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.parkreldis.2011.10.016","article-title":"Body mass index in Parkinson's disease: a meta-analysis","volume":"18","author":"van der Marck","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"10.1016\/j.lpm.2017.01.001_bib0380","doi-asserted-by":"crossref","first-page":"e0131778","DOI":"10.1371\/journal.pone.0131778","article-title":"Body mass index and risk of Parkinson's disease: a dose-response meta-analysis of prospective studies","volume":"10","author":"Wang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.lpm.2017.01.001_bib0385","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.clineuro.2015.11.002","article-title":"Association between subthalamic nucleus deep brain stimulation and weight gain: results of a case-control study","volume":"140","author":"Strowd","year":"2016","journal-title":"Clin Neurol Neurosurg"},{"issue":"21","key":"10.1016\/j.lpm.2017.01.001_bib0390","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1212\/01.wnl.0000312511.62699.a8","article-title":"Total cholesterol and the risk of Parkinson disease","volume":"70","author":"Hu","year":"2008","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.lpm.2017.01.001_bib0395","doi-asserted-by":"crossref","first-page":"e1004741","DOI":"10.1371\/journal.pgen.1004741","article-title":"Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation","volume":"10","author":"Lazaro","year":"2014","journal-title":"PLoS Genet"},{"issue":"10","key":"10.1016\/j.lpm.2017.01.001_bib0400","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/aje\/kwj283","article-title":"Serum cholesterol levels and the risk of Parkinson's disease","volume":"164","author":"de Lau","year":"2006","journal-title":"Am J Epidemiol"},{"issue":"3","key":"10.1016\/j.lpm.2017.01.001_bib0405","doi-asserted-by":"crossref","first-page":"e0152564","DOI":"10.1371\/journal.pone.0152564","article-title":"Statin use and the risk of Parkinson's disease: an updated meta-analysis","volume":"11","author":"Bai","year":"2016","journal-title":"PLoS One"},{"issue":"16 Pt 2","key":"10.1016\/j.lpm.2017.01.001_bib0410","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1212\/01.wnl.0000286942.14552.51","article-title":"Statin use and the risk of Parkinson disease","volume":"70","author":"Wahner","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.lpm.2017.01.001_bib0415","first-page":"5780809","article-title":"Risk of Parkinson's disease in the users of antihypertensive agents: an evidence from the meta-analysis of observational studies","volume":"2016","author":"Mullapudi","year":"2016","journal-title":"J Neurodegener Dis"},{"issue":"7148","key":"10.1016\/j.lpm.2017.01.001_bib0420","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/nature05865","article-title":"\u2019Rejuvenation\u2019 protects neurons in mouse models of Parkinson's disease","volume":"447","author":"Chan","year":"2007","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.lpm.2017.01.001_bib0425","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1002\/mds.25639","article-title":"Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD)","volume":"28","author":"Parkinson Study Group","year":"2013","journal-title":"Mov Disord"},{"issue":"11","key":"10.1016\/j.lpm.2017.01.001_bib0430","doi-asserted-by":"crossref","first-page":"e003620","DOI":"10.1136\/bmjopen-2013-003620","article-title":"Low uric acid levels in patients with Parkinson's disease: evidence from meta-analysis","volume":"3","author":"Shen","year":"2013","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.lpm.2017.01.001_bib0435","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/jamaneurol.2013.5528","article-title":"Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial","volume":"71","author":"Parkinson Study Group S-PDI","year":"2014","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.lpm.2017.01.001_bib0440","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/mds.26483","article-title":"Oral inosine persistently elevates plasma antioxidant capacity in Parkinson's disease","volume":"31","author":"Bhattacharyya","year":"2016","journal-title":"Mov Disord"},{"issue":"17","key":"10.1016\/j.lpm.2017.01.001_bib0445","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1212\/WNL.0b013e3181bd80c1","article-title":"Anemia or low hemoglobin levels preceding Parkinson disease: a case-control study","volume":"73","author":"Savica","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.lpm.2017.01.001_bib0450","doi-asserted-by":"crossref","first-page":"29651","DOI":"10.1038\/srep29651","article-title":"Newly diagnosed anemia increases risk of parkinson's disease: a population-based cohort study","volume":"6","author":"Hong","year":"2016","journal-title":"Sci Rep"},{"issue":"13","key":"10.1016\/j.lpm.2017.01.001_bib0455","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1002\/mds.23230","article-title":"Anxious personality predicts an increased risk of Parkinson's disease","volume":"25","author":"Bower","year":"2010","journal-title":"Mov Disord"},{"issue":"9","key":"10.1016\/j.lpm.2017.01.001_bib0460","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/mds.23092","article-title":"Depression and the subsequent risk of Parkinson's disease in the NIH-AARP Diet and Health Study","volume":"25","author":"Fang","year":"2010","journal-title":"Mov Disord"},{"issue":"16","key":"10.1016\/j.lpm.2017.01.001_bib0465","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1002\/mds.23388","article-title":"Gender differences in Parkinson's disease: clinical characteristics and cognition","volume":"25","author":"Miller","year":"2010","journal-title":"Mov Disord"},{"issue":"7","key":"10.1016\/j.lpm.2017.01.001_bib0470","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1440-1681.2007.04616.x","article-title":"Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease","volume":"34","author":"Liu","year":"2007","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"3","key":"10.1016\/j.lpm.2017.01.001_bib0475","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1212\/01.wnl.0000280573.30975.6a","article-title":"Increased risk of parkinsonism in women who underwent oophorectomy before menopause","volume":"70","author":"Rocca","year":"2008","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.lpm.2017.01.001_bib0480","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2165\/11316780-000000000-00000","article-title":"NSAID use and the risk of Parkinson's disease: systematic review and meta-analysis of observational studies","volume":"26","author":"Samii","year":"2009","journal-title":"Drugs Aging"},{"issue":"2","key":"10.1016\/j.lpm.2017.01.001_bib0485","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1471-4159.2008.05388.x","article-title":"PPAR: a therapeutic target in Parkinson's disease","volume":"106","author":"Chaturvedi","year":"2008","journal-title":"J Neurochem"},{"issue":"12","key":"10.1016\/j.lpm.2017.01.001_bib0490","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1212\/WNL.0b013e3181d5a4a3","article-title":"Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis","volume":"74","author":"Gagne","year":"2010","journal-title":"Neurology"},{"issue":"9766","key":"10.1016\/j.lpm.2017.01.001_bib0495","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(10)62345-8","article-title":"Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies","volume":"377","author":"International Parkinson Disease Genomics Consortium","year":"2011","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.lpm.2017.01.001_bib0500","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/jnc.13593","article-title":"Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance","volume":"139","author":"Hernandez","year":"2016","journal-title":"J Neurochem"},{"issue":"9","key":"10.1016\/j.lpm.2017.01.001_bib0505","doi-asserted-by":"crossref","first-page":"2180e1","DOI":"10.1016\/j.neurobiolaging.2014.03.024","article-title":"Novel alpha-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology","volume":"35","author":"Pasanen","year":"2014","journal-title":"Neurobiol Aging"},{"issue":"5646","key":"10.1016\/j.lpm.2017.01.001_bib0510","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1090278","article-title":"alpha-Synuclein locus triplication causes Parkinson's disease","volume":"302","author":"Singleton","year":"2003","journal-title":"Science"},{"issue":"9440","key":"10.1016\/j.lpm.2017.01.001_bib0515","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0140-6736(04)17103-1","article-title":"\u03b1-synuclein locus duplication as a cause of familial Parkinson's disease","volume":"364","author":"Chartier-Harlin","year":"2004","journal-title":"Lancet"},{"issue":"9440","key":"10.1016\/j.lpm.2017.01.001_bib0520","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0140-6736(04)17104-3","article-title":"Causal relation between \u03b1-synuclein locus duplication as a cause of familial Parkinson's disease","volume":"364","author":"Ib\u00e1\u00f1ez","year":"2004","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.lpm.2017.01.001_bib0525","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.parkreldis.2010.11.008","article-title":"Genetic characteristics of leucine-rich repeat kinase 2 (LRRK2) associated Parkinson's disease","volume":"17","author":"Bardien","year":"2011","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.lpm.2017.01.001_bib0530","article-title":"An updated review of Parkinson's disease genetics and clinicopathological correlations","author":"Ferreira","year":"2016","journal-title":"Acta Neurol Scand"},{"issue":"6","key":"10.1016\/j.lpm.2017.01.001_bib0535","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/gm566","article-title":"Genetics and genomics of Parkinson's disease","volume":"6","author":"Lin","year":"2014","journal-title":"Genome Med"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.lpm.2017.01.001_bib0540","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1002\/mds.22798","article-title":"The role of parkin in familial and sporadic Parkinson's disease","volume":"25","author":"Dawson","year":"2010","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.lpm.2017.01.001_bib0545","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/ana.20587","article-title":"Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers","volume":"58","author":"Pramstaller","year":"2005","journal-title":"Ann Neurol"},{"issue":"17","key":"10.1016\/j.lpm.2017.01.001_bib0550","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease","volume":"361","author":"Sidransky","year":"2009","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.lpm.2017.01.001_bib0555","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s10571-015-0176-8","article-title":"Gaucher-associated Parkinsonism","volume":"35","author":"Li","year":"2015","journal-title":"Cell Mol Neurobiol"},{"issue":"Suppl 1","key":"10.1016\/j.lpm.2017.01.001_bib0560","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/jnc.13385","article-title":"The relationship between glucocerebrosidase mutations and Parkinson disease","volume":"139","author":"Migdalska-Richards","year":"2016","journal-title":"J Neurochem"},{"issue":"Pt A","key":"10.1016\/j.lpm.2017.01.001_bib0565","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.mcn.2015.03.013","article-title":"Glucocerebrosidase and Parkinson disease: recent advances","volume":"66","author":"Schapira","year":"2015","journal-title":"Mol Cell Neurosci"},{"issue":"7601","key":"10.1016\/j.lpm.2017.01.001_bib0570","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nature17939","article-title":"Parkinson-associated risk variant in distal enhancer of alpha-synuclein modulates target gene expression","volume":"533","author":"Soldner","year":"2016","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.lpm.2017.01.001_bib0575","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/mds.26152","article-title":"Statins, plasma cholesterol, and risk of Parkinson's disease: a prospective study","volume":"30","author":"Huang","year":"2015","journal-title":"Mov Disord"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498217300015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498217300015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T12:52:46Z","timestamp":1568811166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498217300015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0755498217300015"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2017.01.001","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epidemiology, environmental risk factors and genetics of Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2017.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}